2004
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342. Journal Of Clinical Oncology 2004, 22: 2061-2068. PMID: 15169793, DOI: 10.1200/jco.2004.08.048.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerQuality of lifeOptimal doseResponse rateSignificant dose-response relationshipHigh-dose armPrior chemotherapy regimensHigh-dose therapySymptom assessment questionnaireCycles of treatmentSelf-administered qualitySignificant differencesDose-response relationshipChemotherapy regimensDose therapyHematologic toxicityDose armAssessment QuestionnaireHigh dosesMultivariate analysisSignificant associationInfusionCancerRegimens
2001
Quality of Life Issues Among Women Undergoing High-Dose Chemotherapy for Breast Cancer
Partridge A, Bunnell C, Winer E. Quality of Life Issues Among Women Undergoing High-Dose Chemotherapy for Breast Cancer. Breast Disease 2001, 14: 41-50. PMID: 15687635, DOI: 10.3233/bd-2001-14106.Peer-Reviewed Original ResearchHigh-dose chemotherapyOverall QoLPhysical functioningBreast cancerAutologous stem cell supportHigh-dose therapyStem cell supportDose chemotherapyTransplant resultsPatients' qualityConsiderable symptomsQoL findingsRole functioningTransient impairmentChemotherapyCell supportQoLSexual functioningLife issuesPatientsCognitive functioningTherapySymptomsCancerAdditional research
2000
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma
Dawson N, Conaway M, Halabi S, Winer E, Small E, Lake D, Vogelzang N. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. Cancer 2000, 88: 825-834. PMID: 10679652, DOI: 10.1002/(sici)1097-0142(20000215)88:4<825::aid-cncr13>3.0.co;2-n.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate carcinomaMegestrol acetateProstate carcinomaStable diseasePartial responsePerformance statusDay doseHigh-dose megestrol acetateEnd pointPossible dose-response effectDose megestrol acetateHigher baseline PSAOral megestrol acetateHigh-dose therapyPoor performance statusPrimary end pointSecondary end pointsMedian survival timeAdvanced prostate carcinomaDose-response effectDose-response correlationEvaluable diseaseMeasurable diseaseDose therapyBaseline PSA